Small Molecule Reprogramming of Fibroblasts to Neural Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing induced pluripotent stem cells (iPS) face challenges due to the risks associated with viral transfection vectors and oncogenic transcription factors, which hinder the clinical utilization of pluripotent stem cells for treating human diseases.
Innovation Solution
A method involving the use of small molecules, such as G9a HMTase inhibitors and MEK inhibitors, to induce fibroblasts into multipotent stem cells like neural stem cells without the need for viral transfection vectors or oncogenic transcription factors, utilizing a combination of small molecules like BIX01294, RG108, and PD325901 to de-differentiate fibroblasts into neural stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral transfection vectors and oncogenic transcription factors are used for reprogramming, then stem cell induction efficiency is improved, but safety and reliability deteriorate due to cancer risks
Solution Approach 1:
The patent extracts and removes the harmful viral transfection vectors and oncogenic transcription factors from the reprogramming process. Instead, it uses only small molecule compounds (such as G9a HMTase inhibitors and MEK inhibitors) to induce fibroblasts into multipotent stem cells, thereby eliminating the safety risks while maintaining reprogramming capability
Solution Approach 2:
The patent replaces the complex, potentially harmful viral vectors with simple, non-integrating small molecule compounds that do not permanently alter the genome. These small molecules act temporarily to induce reprogramming without leaving persistent genetic elements that could cause cancer
2Adaptability or versatility
If viral transfection vectors are used for reprogramming, then reprogramming capability is improved, but manufacturing precision and purity deteriorate due to genomic integration risks
Solution Approach 1:
The patent substitutes the mechanical/genetic approach of viral transfection with a chemical approach using small molecule compounds. Instead of physically inserting genetic material that integrates into the genome, small molecules chemically modulate cellular pathways to achieve reprogramming without genomic integration
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that mediate the reprogramming process. These molecules temporarily alter cellular state and gene expression patterns to induce multipotency, then are removed without leaving permanent genetic changes
Data Source
AI summary
The present invention provides a method of producing a multipotent stem cell, said method comprising culturing at least one fibroblast cell in the presence of an effective amount of at least one small molecule reprogramming factor(s) that induces the cell to de-differentiate into a multipotent stem cell, wherein the method excludes the use of reprogramming factor(s) that are not small molecules. The small molecule reprogramming factor(s) may include a G9a HMTase inhibitor(s) and/or a MEK inhibitor(s) optionally in combination with other small molecule reprogramming factor(s). The invention also includes methods of differentiating the multipotent stem cells, cells produced by the methods, assays using the cells and kits for use in the methods.